Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

Moderna MRNA provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Equities researchers at William Blair raised their FY2024 EPS estimates for shares of Moderna in a research report issued to ...

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...

Moderna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...

Berenberg Bank analyst Harry Gillis maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $33.00.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...